Question · asked by 1 review
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment: Adverse events,
- Population
- stage III and IV cutaneous melanoma
- Intervention
- Neoadjuvant immunotherapy (talimogene laherparepvec)
- Comparison
- no neoadjuvant treatment
- Outcome
- Adverse events,
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment Adverse Events, · stage III and IV cutaneous melanoma It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty). Neoadjuvant treatment for stage III and IV cutaneous melanoma (2023) · Cochrane Headline outcomes only | RR 2.84 [0.96, 8.37] | 1 study · 142 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.